Merck's Januvia demonstrates glucose-lowering effect in type 2 diabetes

By Lisa Kerner

Charlotte, N.C., June 13 - Merck & Co., Inc. said a study comparing Januvia (sitagliptin phosphate) to glipizide (a sulfonylurea) showed Januvia was non-inferior to glipizide in reducing blood sugar levels in patients with type 2 diabetes.

Additionally, Januvia demonstrated weight loss benefits and fewer episodes of hyperglycemia.

The 52-week data presented were the primary time point analysis for the double-blind, randomized study, which continues for another year, according to a company news release.

If approved, the investigational once-daily Januvia would potentially be the first in a new class of oral drugs (dipeptidyl peptidase-4 (DPP-4) inhibitors) that enhances the body's own ability to lower blood sugar (glucose).

Merck presented the data at the American Diabetes Association 66th Annual Scientific Sessions in Washington, D.C.

Located in Whitehouse Station, N.J., Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.